Short answer
Theravance Biopharma, Inc. (TBPH) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $20M (up 18.5% year over year) with net income of $4M.
Q3 2025 key financials · XBRL
- Revenue
- $20M
- +18.5% YoY · −23.7% QoQ
- Net income
- $4M
- +128.5% YoY · −93.4% QoQ
- Operating margin
- -32.3%
- EPS (diluted)
- $0.07
- +126.9% YoY · −93.5% QoQ
Source: XBRL data from the Theravance Biopharma, Inc. (TBPH) Q3 2025 10-Q on SEC EDGAR. USD.
Theravance Biopharma, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $20.0M, up 19% YoY from $16.9M, driven by higher YUPELRI sales
- YUPELRI net sales $71.4M, up 15% YoY from $62.2M; implied company share $25.0M
- R&D expense $8.1M, down 12% YoY from $9.3M after CYPRESS enrollment completion
- China approval generated $7.5M licensing revenue during nine months ended September 30, 2025
- CYPRESS top-line data expected in first quarter 2026; YUPELRI pricing improvements likely to moderate
Risk Factors
- Strategic review process, formed November 2024, may fail to produce a transaction and increase operating disruption
- YUPELRI pricing headwinds from evolved channel mix and lower realized net price
- Ampreloxetine Phase 3 CYPRESS study faces endpoint, safety, enrollment, and regulatory-approval uncertainty
- New COPD competition from ensifentrine, launched June 2024, and Dupixent approval
- Profitability dependent on $44.9 million nine-month 2025 income largely from one-time TRELEGY royalty-sale gain
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Theravance Biopharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.